Quality of life in elderly patients with acute myeloid leukemia: Patients may be more accurate than physicians

Haematologica

Volumn 96, Issue 5, 2011, Pages 696-702

  Oliva, Esther N ^a   Nobile, Francesco ^a   Alimena, Giuliana ^b   Ronco, Francesca ^a   Specchia, Giorgina ^c   Impera, Stefana ^d   Breccia, Massimo ^b   Vincelli, Iolanda ^a   Carmosino, Ida ^b   Guglielmo, Patrizia ^d   Pastore, Domenico ^c   Alati, Caterina ^a   Latagliata, Roberto ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Hematology Division   (Italy)

Author keywords

Aml; Elderly; Intensive chemotherapy; Quality of life

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHYSICIAN; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SELF CONCEPT;

ACUTE DISEASE; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 79955705862     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036715     Document Type: Article

References (27)

1. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep. 1985;69(1):5-11.
2. Latagliata R, Petti MC, Mandelli F. Acute myeloid leukemia in the elderly: ''per aspera ad astra''? Leuk Res 1999;23(7):603-13.
3. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116(22):4422-9.
4. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukaemia. J Clin Oncol. 2006;24 (16):2480-9.
5. Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOLEAMS. J Clin Oncol. 2010;28(18):3028-4.
6. Tamburrini LR, Di Monte M, Gerometta R, Ponte E, Cherubini M. The aging heart and its pathology. An epidemiological study of 229 cases based on a clinical and radiological classification. Minerva Med. 1989;80 (12):1275-82.
7. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med. 1986;80(3):435-42.
8. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89 (9):3323-9.
9. Burnett. AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparirison of low-dose cytarabine and hydroxyurea with or without all-trans Retinoic acid for acute myeloid leukemia and high-risk myelodisplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-24.
10. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med. 1993;118(8):622-9.
11. Hickey A, Barker M, McGee H, O'Boyle C. Measuring health-related quality of life in older patient populations: a review of current approaches. Pharmacoeconomics. 2005;23(10):971-93.
12. Sajid MS, Tonsi A, Baig MK. Health-related quality of life measurement. Int J Health Care Qual Assur. 2008;21(4):365-73.
13. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12(3):608-16.
14. Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, el al. The European Organization for Research and Treatment of Cancer QLQ-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.
15. Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P. Evaluation of the EORTC QLQC30 questionaire: a comparison with SF-36 Health Survey in a cohort of Italian long survival cancer patients. Ann Oncol. 1998; 9(5):549-57.
16. Oliva EN, D'Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol. 2002;20(14):3182-4.
17. Oliva EN, Dimitrov BD, Benedetto F, D'Angelo A, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res. 2005;29(10):1217-9.
18. Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, et al. Darbepoetin for the treatment of anemia of myelodysplastic syndromes: efficacy and quality of life. Leuk Lymph. 2010;51(6):1007-14.
19. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26(8):1355-63.
20. Gupta D, Lis CG, Grutsch JF. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire: implications for prognosis in pancreatic cancer. Int J Gastrointest Cancer. 2006;37(2-3):65-73.
21. Strasser-Weippl K, Ludwig H. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur J Haematol. 2008;81(5):374-9.
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
23. Mauer ME, Bottomley A, Coens C. Statistical methodology is crucial in prognostic factor analysis of health-related quality of life. Qual Life Res. 2008;17(7):1043-4.
24. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97(3):302-7.
25. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865-71.
26. Meyer F, Fortin A, Gélinas M, Nabid A, Brochet F, Têtu B, et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol. 2009;27(18):2970-6.
27. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML 11 and LRF AML 14 trials. Br J Haematol. 2009;145(5):598-605.